{
	"kja6iuumText": "Montgomer<span class=\"_ _1\"></span>y SA et<span class=\"_ _0\"></span> al. 20<span class=\"_ _c\"></span>1<span class=\"_ _3\"></span>4<span class=\"_ _3\"></span><span class=\"fs1 ls5 v1\">1</span>",
	"kja6iuunText": "<div style=\"line-height: 1;\"><font style=\"font-size: 38px;\">A randomised, double-blind study in adults with MDD with a suboptimal response to a<br>single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake<br>inhibitor treatment switched to Brintellix® or agomelatine.</font></div><div style=\"line-height: 1; margin-top:5px;\"><font style=\"font-size: 38px;\">Study objective: <span class=\"ff3\">Compare the efficacy of flexible doses of Brintellix® with agomelatine, after<br>eight weeks of treatment, on depressive symptoms in patients with MDD who have responded<br>inadequately to antidepressant monotherapy with an SSRI or SNRI.</span></font></div>",
	"kja6iuuoText": "Primary ef<span class=\"_ _0\"></span>ficac<span class=\"_ _0\"></span>y endpoint: <span class=\"ff3\">ch<span class=\"_ _2\"></span>ange fr<span class=\"_ _2\"></span>om base<span class=\"_ _2\"></span>lin<span class=\"_ _2\"></span>e in MADR<span class=\"_ _2\"></span>S <br><span class=\"wsb\">total sc<span class=\"_ _2\"></span>ore at w<span class=\"_ _c\"></span>eek 8 based on th<span class=\"_ _2\"></span>e full a<span class=\"_ _2\"></span>naly<span class=\"_ _2\"></span>sis set us<span class=\"_ _2\"></span>ing a<span class=\"_ _2\"></span>ll <br>av<span class=\"_ _2\"></span>ail<span class=\"_ _2\"></span>abl<span class=\"_ _2\"></span>e data. A no<span class=\"_ _2\"></span>n-infe<span class=\"_ _2\"></span>riority fol<span class=\"_ _2\"></span>low<span class=\"_ _2\"></span>ed by a su<span class=\"_ _2\"></span>peri<span class=\"_ _2\"></span>ority <br>compari<span class=\"_ _2\"></span>son of B<span class=\"_ _2\"></span>rint<span class=\"_ _2\"></span>ell<span class=\"_ _2\"></span>ix® vs. ago<span class=\"_ _2\"></span>mela<span class=\"_ _2\"></span>tine w<span class=\"_ _2\"></span>as based o<span class=\"_ _2\"></span>n <br>estimat<span class=\"_ _2\"></span>es from a m<span class=\"_ _2\"></span>ixe<span class=\"_ _2\"></span>d model f<span class=\"_ _2\"></span>or re<span class=\"_ _2\"></span>peat<span class=\"_ _2\"></span>ed meas<span class=\"_ _2\"></span>ure<span class=\"_ _2\"></span>ments.</span></span>",
	"kja6iuupText": "Secondary e<span class=\"_ _0\"></span>f<span class=\"_ _0\"></span>ficac<span class=\"_ _0\"></span>y endpoints: <span class=\"ff3 ls28 ws6d\">inclu<span class=\"_ _0\"></span>ded H<span class=\"_ _0\"></span>AM<span class=\"_ _0\"></span>-A <br><span class=\"ls5 wsb\">total scor<span class=\"_ _2\"></span>e, C<span class=\"_ _c\"></span>GI-S and C<span class=\"_ _2\"></span>GI-l scor<span class=\"_ _2\"></span>es, SD<span class=\"_ _c\"></span>S total scor<span class=\"_ _2\"></span>e, <br>E<span class=\"_ _2\"></span>Q-5D o<span class=\"_ _2\"></span>ve<span class=\"_ _2\"></span>rall h<span class=\"_ _2\"></span>ealth state sco<span class=\"_ _2\"></span>re (V<span class=\"_ _c\"></span>AS), W<span class=\"_ _2\"></span>L<span class=\"_ _2\"></span>Q glo<span class=\"_ _2\"></span>bal <br>pr<span class=\"_ _2\"></span>oductivity index a<span class=\"_ _2\"></span>nd DF<span class=\"_ _2\"></span>FS to<span class=\"_ _2\"></span>tal scor<span class=\"_ _2\"></span>e.</span></span>",
	"kja6iuuqText": "<div style=\"text-align: center;\">Randomisation</div><div style=\"text-align: center;\">1:1<span class=\"_ _0\"></span>&nbsp;(<span class=\"_ _1\"></span>A<span class=\"_ _0\"></span>P<span class=\"_ _1\"></span>T<span class=\"_ _0\"></span>S<span class=\"_ _1\"></span>=<span class=\"_ _0\"></span>4<span class=\"_ _0\"></span>9<span class=\"_ _0\"></span>5)<br></div>",
	"kja6iuusText": "Patients seen at <br>baseline, and<span class=\"_ _0\"></span> <br><span class=\"ls1a wsb\">weeks 1<span class=\"_ _c\"></span>, 2, 3, 4, <br>8 and 12</span>",
	"kja6iuutText": "12-week double blind treatment period",
	"kja6iuuuText": "<div style=\"line-height: 1.2;\">Key inclusion criteria <br style=\"\"><span class=\"ff3\">P<span class=\"_ _c\" style=\"\"></span>atients with a primary<span class=\"_ _0\"></span> <br>diagnosis of a single<span class=\"_ _0\"></span> <br>episode or recurrent <br>MDD according to DSM-IV <br>criteria 18-75 years of age <br>Current MDE duration of  <br>&lt;12 months <br>MADRS total score of<span class=\"_ _0\"></span> ≥22 <br>and item 1 score (apparent <br>sadness) of<span class=\"_ _0\"></span> ≥3 at screening <br>and baseline <br>Non or partially <br>responsive to a single<span class=\"_ _0\"></span> <br>trea<span class=\"_ _2\"></span>tment course of an<span class=\"_ _0\"></span> <br>adequate dose and <br>duration (≥6 weeks)</span></div>",
	"kja6iuuvText": "Brintellix® 10-20 mg/day <br><span class=\"ws71\">(n=253) </span><span class=\"ff3\">10 mg/day in W<span class=\"_ _2\"></span>eek 1. <br>At the end of weeks 1, 2,<span class=\"_ _c\"></span> 3 or 4, </span><div><span class=\"ff3\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">the dose could be increased to&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">20 mg/day</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">. Investigator could&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">decr</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">ease dose to 10 mg/day if</span><span class=\"_ _0\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">requir</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">ed due to intolerability</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">.&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">After W</span><span class=\"_ _c\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">eek 4, dose was fixed</span><br></span></div>",
	"kja6iuuxText": "<div style=\"line-height: 1.3;\"><div style=\"text-align: center;\">F<span class=\"_ _2\" style=\"\"></span>our-week</div><div style=\"text-align: center;\">safety<br style=\"\"></div><div style=\"text-align: center;\"><span style=\"text-align: start;\">follow up</span><br></div></div>",
	"kja6iuv0Text": "Agomelatine 25-50 mg/day <br><span class=\"ws71\">(n=242) </span><span class=\"ff3\">25 mg/day for the first <br>two weeks of treatment.<span class=\"_ _2\"></span> At the </span><div><span class=\"ff3\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">end of weeks 2, 3 or 4, the dose&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">could be increased to 50 mg/day</span><span class=\"_ _c\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">.&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">Investigator could decrease dose&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">to 25 mg/day if required due to&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">intolerability</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">.&nbsp;</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">After week 4,</span><span class=\"_ _2\" style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"></span><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">&nbsp;dose&nbsp;</span><br style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\"><span style=\"font-family: &quot;3_JLVNQG+AvenirNextLTPro-Regular&quot;;\">was fixed</span><br></span></div>",
	"kja6iuv2Text": "Back",
	"Brintellix_71651629ac": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_71dc2c4d57": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Montgomery SA et al. Hum Psychopharmacol Clin Exp 2014;29:470-482.</div>"
}
